Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 896

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 12
Chunk 896
---
$1,472 Current provisions relating to sales in the current year1,300 2,593 399 4,292 Adjustments relating to prior years(39)(711)(45)(795)Payments/returns relating to sales in the current year(1,079)(1,239)— (2,318)Payments/returns relating to sales in the prior years(85)(373)(97)(555)Balance at December 31, 2024$253 $1,354 $489 $2,096 (In thousands)Contractual AdjustmentsGovernment RebatesReturnsTotalBalance at December 31, 2022$65 $573 $133 $771 Current provisions relating to sales in the current year1,079 2,086 2,182 5,347 Adjustments relating to prior years— (237)(77)(314)Payments/returns relating to sales in the current year(938)(1,003)(1,958)(3,899)Payments/returns relating to sales in the prior years(50)(335)(48)(433)Balance at December 31, 2023$156 $1,084 $232 $1,472 

F-19

Total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:(In thousands)December 31, 2024December 31, 2023Reduction of accounts receivable$124 $151 Component of accrued expenses 1,972 1,321 Total revenue-related reserves$2,096 $1,472 The following table presents changes in our contract assets, which consisted of accounts receivable, net: (In thousands)December 31, 2024December 31, 2023Beginning balance$2,810 $2,206    Additions (1)39,973 31,855    Deductions (1)(38,674)(31,251)Ending balance$4,109 $2,810 

(1)  Additions to contract assets relate to amounts billed to Customers for product sales, and deductions to contract assets primarily relate to collection of receivables during the reporting period. 

Note 9. Share-Based Payments 

2023 Stock Incentive Plan and Inducement GrantsIn June 2023, our stockholders approved the 2023 Stock Incentive Plan, or the 2023 Plan. The 202